| abstract |
An immune-regulatory vaccine comprising—a directed adjuvant comprising at least an anti-CD32 moiety linked to a TLR9 ligand and a first peptidic alpha-helix, and—an immunogen with at least one epitope and a second peptidic alpha-helix coiled to the first alpha-helix, a kit for preparing the vaccine, and a sensibilizing vaccine comprising at least an anti-CD32 moiety linked to a TLR9 ligand and a peptidic alpha-helix in a pharmaceutical formulation. |